MITRO owns a professional radiolabeling team that can offer radiolabelling serivce for pre-clinical and clinical studies and syntheize isotopic tracers for different purposes.
MITRO's professional radiochemistry team can label small molecule drugs, antibodies, large molecule drugs, polymer drugs, antibody drug conjugates (ADCs), cells by positron-emitter isotopes including 11C, 18F, 64Cu, 68Ga, 89Zr,124I and solid-phase isotopes including 99mTc and 131I.
MITRO has already synthesized the many tracers and these tracers are used in different studies.
MITRO Biotech Co., Ltd. is the first company in China that provides pre-clinical and clinical contract research services by applying molecular imaging technologies.
MITRO is capable of using radioisotopes and molecular imaging technologies to conduct drug screening, biodistribution, PD and PK studies.
MITRO owns a professional radionuclide labeling and experiment team that can offer 125I labeling of different specific activity and perform stability evaluation studies.
Molecular imaging technique can simulate in vivo pharmacokinetics and pharmacodynamics for investigating in vivo ADME/DMPK and efficacy evaluation of drugs at the molecular level.
Antibody PET, also known as ImmunoPET, is a promising diagnostic technique that combines the high sensitivity, high resolution and quantitative analysis of PET with the high specificity of antibodies and aims to improve the efficiency of cancer diagnosis.
MITRO provides radiolabeling services for a variety of cells, including stem cells, T cells, bacteria, yeasts and fungi, to observe their dynamic variation processes in vivo.
Currently, PET imaging is mainly used to detect the targets and mechanisms of antineoplastic drugs, predict the sensitivity and resistance of drugs, and assess the treatment effects of chemotherapy and radiotherapy.
MITRO can use PET imaging technique to evaluate in-vivo candidate drugs' receptor occupancy, receptor affinity and assess drugs' pharmacodynamics and mechanisms.
PET imaging, as the only accurate myocardial viability determination method currently, is the "golden standard" for assessing myocardial viability, prognosis and drug efficacy.
MITRO also provides services for immune system and skeletal system diseases studies.
MITRO is competent to perform Phase 0 and clinical bridging studies by utilizing the advantages of molecular imaging.
MITRO uses PET/SPECT and other molecular imaging technologies to provide phase 0 research services for new drugs.
MITRO uses PET/SPECT and other molecular imaging technologies to provide ethnic difference research services for new drugs.
MITRO delivers all-round registration consultation, professional technical services and regulatory compliance advices on radiopharmaceuticals to pharmaceutical companies around the world.
Immunology
Bone Diseases
